Navigation Links
GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
Date:11/18/2011

SAN DIEGO, Nov. 18, 2011 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., today announced study results and the commercial launch of PREvent™. FirstMark PREvent is the first multiple biomarker test that accurately predicts near term (approximately 2-3 years) risk of myocardial infarction (MI) for suspected or confirmed coronary artery disease (CAD) patients. FirstMark PREvent was launched, and the data from the phase I prospective study entitled, "Aggregate Risk Score Based on Markers of Inflammation, Immunity, and Thrombosis is an Independent Predictor of Adverse Cardiovascular Outcomes," was presented by Danny J. Eapen, MD, at the American Heart Association Scientific Sessions 2011 (AHA), in Orlando, Florida.

PREvent is a simple blood test based on technology developed and patented by GenWay, Emory University and MedStar. The test aggregates three biomarkers that identify the multiple pathways that lead to vulnerable plaques. The development and validation studies for the test were comprised of approximately 3,000 individuals with suspected or confirmed CAD. The studies showed PREvent to be significantly more powerful than other tests and risk factors, by identifying the top 10% of confirmed CAD patients that are at a 6.45 times higher risk of a near term MI within a 2-3 year period, as compared to other CAD patients. The test also proved to be 12 times more powerful than the single biomarker CRP. In addition, 18% of CAD patients with all three biomarkers elevated had a major event within the first year, compared to only 2% of CAD patients with normal biomarker levels.

PREvent is a critical advancement in cardiovascular medicine addressing the unmet need to access risk of near term MI. "This simple blood test is an exciting development for suspected or confirmed CAD patients, allowing physician's diagnostic clarity in identifying CAD patients that are in most urgent need of aggressive treatment and monitoring," said Thomas Silberg, President and CEO of GenWay Biotech. FirstMark PREvent is now available and will be targeted to primary care physicians and cardiologists.

The AHA Scientific Sessions 2011 abstract and additional information about the test is available at http://www.FirstMarkPREvent.com

About GenWay Biotech, Inc.
GenWay Biotech, is comprised of three divisions. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. GenWay's catalog products and custom services divisions are focused on protein and antibody solutions. GenWay's headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area.

Media Contact: Deborah Moore GenWay Biotech, Inc., 858-458-0855, dmoore@genwaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE GenWay Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Acquires Seppro(R) Depletion Technology From GenWay Biotech
2. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
3. Yongye Biotechnology International Retains CCG Investor Relations
4. ThirdBiotech Announces Kemeta as Newest Sponsor
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
7. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
8. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
9. China Kangtai Cactus Biotech Announces Record Second Quarter Results
10. Yongye Biotechnology International Announces Second Quarter Results
11. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):